Characteristics of dose-dependent antagonism by beta-funaltrexamine of the antinociceptive effects of intrathecal mu agonists

E Mjanger and TL Yaksh

Department of Anesthesiology, Medical College of Wisconsin, Milwaukee.

Using rats with chronic i.t. catheters, dose-response curves were carried out using the hot plate (HP) test for a number of receptor- preferring opioids. The ordering of activity (i.t. ED50; nmol) on the HP was: (D-Ala2, N-Me-Phe4, Gly5-ol) enkephalin (DAMGO 0.5); sufentanil (0.4); and morphine (6.6). To assess the effects of pretreatment with the irreversible mu ligand beta-funaltrexamine (beta-FNA), rats received saline, 0.2, 2.0 or 20.0 nmol of beta-FNA. After 24 hr, base- line response latencies were not different from control animals. Dose- response curves for morphine, sufentanil and DAMGO were then obtained. Pretreatment with beta-FNA resulted in a concentration-dependent rightward shift in the agonist dose-response curves with the dose-ratio values of the respective doses of beta-FNA being for morphine: 3.5, 15.7, and 37.3; sufentanil: 1.2, 1.9, and 5.3; and DAMGO: 1.9, 4.0 and 7.3. The slopes of the agonist dose-response curves also displayed mild reductions in slope, the magnitude of which was dependent upon beta-FNA pretreatment concentrations. Testing at 6 days after beta-FNA treatment revealed a significant recovery of effect. beta-FNA (20 nmol, i.t.) had no effect on a just maximally effective dose of ST-91 (90 nmol, i.t.), an alpha-2 adrenergic agonist. beta-FNA (20 nmol, i.t.), but not 2.0 nmol resulted in a modest but significant reduction in the effect of the delta agonist DPLPE (120 nmol). These data are interpreted as supportive of the hypothesis that the mu-preferring ligands differ in the number of spinal receptors that must be occupied to produce a given antinociceptive effect (i.e., they differ in intrinsic efficacy).

Volume 258, Issue 2, pp. 544-550, 08/01/1991
Copyright © 1991 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				R. H. Kline IV and R. G. Wiley Spinal {micro}-Opioid Receptor-Expressing Dorsal Horn Neurons: Role in Nociception and Morphine Antinociception J. Neurosci., January 23, 2008; 28(4): 904 - 913. [Abstract] [Full Text] [PDF]

				A. C. Barrett, E. S. Smith, and M. J. Picker Use of Irreversible Antagonists to Determine the Relative Efficacy of {micro}-Opioids in a Pigeon Drug Discrimination Procedure: Comparison of {beta}-Funaltrexamine and Clocinnamox J. Pharmacol. Exp. Ther., June 1, 2003; 305(3): 1061 - 1070. [Abstract] [Full Text] [PDF]

				K. A. Sluka, J. J. Rohlwing, R. A. Bussey, S. A. Eikenberry, and J. M. Wilken Chronic Muscle Pain Induced by Repeated Acid Injection Is Reversed by Spinally Administered {micro}- and delta -, but Not kappa -, Opioid Receptor Agonists J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1146 - 1150. [Abstract] [Full Text] [PDF]

				L. Valle, O. Pol, and M. M. Puig Intestinal Inflammation Enhances the Inhibitory Effects of Opioids on Intestinal Permeability in Mice J. Pharmacol. Exp. Ther., April 13, 2001; 296(2): 378 - 387. [Abstract] [Full Text]

				J. H. Broadbear, T. L. Sumpter, T. F. Burke, S. M Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor Methocinnamox Is a Potent, Long-Lasting, and Selective Antagonist of Morphine-Mediated Antinociception in the Mouse: Comparison with Clocinnamox, beta -Funaltrexamine, and beta -Chlornaltrexamine J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 933 - 940. [Abstract] [Full Text]

				M. M. Puig and O. Pol Peripheral Effects of Opioids in a Model of Chronic Intestinal Inflammation in Mice J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 1068 - 1075. [Abstract] [Full Text]

				L. Zhou, Q. Zhang, C. Stein, and M. Schäfer Contribution of Opioid Receptors on Primary Afferent Versus Sympathetic Neurons to Peripheral Opioid Analgesia J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 1000 - 1006. [Abstract] [Full Text]

				R. C. Pitts, R. M. Allen, E. A. Walker, and L. A. Dykstra Clocinnamox Antagonism of the Antinociceptive Effects of Mu Opioids in Squirrel Monkeys J. Pharmacol. Exp. Ther., June 1, 1998; 285(3): 1197 - 1206. [Abstract] [Full Text]

				D. E. Selley, Q. Liu, and S. R. Childers Signal Transduction Correlates of Mu Opioid Agonist Intrinsic Efficacy: Receptor-Stimulated [35S]GTPgamma S Binding in mMOR-CHO Cells and Rat Thalamus J. Pharmacol. Exp. Ther., May 1, 1998; 285(2): 496 - 505. [Abstract] [Full Text]

				J. D. Swenson and P. L. Bailey Opioids in Cardiovascular Anesthesia Seminars in Cardiothoracic and Vascular Anesthesia, July 1, 1997; 1(2): 146 - 163. [PDF]

				D. E. Selley, L. J. Sim, R. Xiao, Q. Liu, and S. R. Childers {micro}-Opioid Receptor-Stimulated Guanosine-5'-O-(gamma -thio)-triphosphate Binding in Rat Thalamus and Cultured Cell Lines: Signal Transduction Mechanisms Underlying Agonist Efficacy Mol. Pharmacol., January 1, 1997; 51(1): 87 - 96. [Abstract] [Full Text]

				J.-G. Liu, M. B. Ruckle, and P. L. Prather Constitutively Active {micro}-Opioid Receptors Inhibit Adenylyl Cyclase Activity in Intact Cells and Activate G-proteins Differently than the Agonist [D-Ala2,N-MePhe4,Gly-ol5]Enkephalin J. Biol. Chem., October 5, 2001; 276(41): 37779 - 37786. [Abstract] [Full Text] [PDF]